Given that the colonic mucosa of patients with IBD is characterized by type I IFN gene signature even with intact Card15 or Otud3 [14,15,18], the blockade of type I IFN responses might be an alternative treatment option for patients with IBD. Here, OTUD3 is linked to inflammatory bowel disease.